

What is Amarin's view on the *GSK v. Teva* litigation being reheard by the Federal Circuit panel that decided the case?

Amarin's pending REDUCE-IT® patent infringement litigation is rooted in its own set of facts and circumstances against Hikma and Health Net and is supported by longstanding Federal Circuit caselaw. Amarin intends to continue to vigorously defend its intellectual property rights through the pending litigation and elsewhere as appropriate. More information can be found on the court docket for the pending Amarin litigation, including, without limitation, in Amarin's docketed response brief, filed on February 10, 2021, to the pending motion to dismiss.

Dated February 10, 2021